Results 11 to 20 of about 3,046,243 (224)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica, 2019
Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children ...
Jean-Christophe Ianotto, Natalia Curto-Garcia, Marie Lauermanova, Deepti Radia, Jean-Jacques Kiladjian, Claire N. Harrison   +5 more
doaj   +2 more sources

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

Mediterranean Journal of Hematology and Infectious Diseases, 2020
Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to determine the thrombotic event, including the interaction between platelets, leukocytes and ...
Vincenzo Accurso, Marco Santoro, Salvatrice Mancuso, Angelo Davide Contrino, Paolo Casimio, Mariano Sardo, Simona Raso, Florinda Di Piazza, Alessandro Perez, Marco Bono, Antonio Russo, Sergio Siragusa   +11 more
doaj   +2 more sources

Pleural Infiltration Revealing Post-Essential Thrombocythemia Acute Myeloid Leukaemia. [PDF]

EJHaem
eJHaem, Volume 6, Issue 6, December 2025.
Muron C, Luque Paz D, Copin MC, Orvain C.   +3 more
europepmc   +2 more sources

Triple A Plus (AAA ⁺) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients. [PDF]

Am J Hematol
A new risk model for essential thrombocythemia that is based on complete blood cell count‐derived parameters and host‐related factors. ABSTRACT Survival prediction models in essential thrombocythemia (ET) include the International Prognostic Scoring System (IPSET) and the more recently introduced triple‐A (AAA) prognostic score.
Tefferi A, Loscocco GG, Rokach L, Tadmor T, Faldu P, Melamed G, Alapi H, Abdelmagid M, Abdelaziz RM, Yousuf M, Nakhleh M, Pardanani A, Begna KH, Patnaik MM, Szuber N, Carobbio A, Barbui T, Reichard KK, He R, Guglielmelli P, Gangat N, Vannucchi AM.   +21 more
europepmc   +2 more sources

A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count

American journal of hematology/oncology, 2023
We examined the individual prognostic contribution of absolute neutrophil (ANC), lymphocyte (ALC), and monocyte (AMC) counts, on overall (OS), leukemia‐free (LFS), and myelofibrosis‐free (MFFS) survival in essential thrombocythemia (ET).
A. Tefferi, G. G. Loscocco, F. Farrukh, N. Szuber, F. Mannelli, A. Pardanani, C. Hanson, R. Ketterling, V. De Stefano, A. Carobbio, T. Barbui, P. Guglielmelli, N. Gangat, A. Vannucchi   +13 more
semanticscholar   +1 more source

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia

Blood, 2022
Therapy for essential thrombocythemia (ET) and polycythemia vera (PV) is aimed at reducing thrombotic risk through normalizing blood counts. Mascarenhas et al report on a randomized trial of hydroxyurea (HU) vs pegylated interferon α (PEG) in 168 ...
J. Mascarenhas, H. Kosiorek, J. Prchal, A. Rambaldi, Dmitriy Berenzon, A. Yacoub, C. Harrison, M. McMullin, A. Vannucchi, J. Ewing, C. O'Connell, J. Kiladjian, A. Mead, E. Winton, D. Leibowitz, V. De Stefano, M. Arcasoy, C. Kessler, R. Catchatourian, D. Rondelli, R. Silver, A. Bacigalupo, A. Nagler, M. Kremyanskaya, M. Levine, J. A. Arango Ossa, E. McGovern, L. Sandy, M. Salama, V. Najfeld, J. Tripodi, N. Farnoud, A. Penson, R. Weinberg, L. Price, J. Goldberg, R. Marchioli, G. Tognoni, R. Rampal, R. Mesa, A. Dueck, R. Hoffman, T. Barbui   +42 more
semanticscholar   +1 more source

SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.

Future Oncology, 2022
Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source.
S. Verstovsek, Norio Komatsu, H. Gill, J. Jin, Sung‐Eun Lee, H. Hou, Toshiaki Sato, A. Qin, Raymond W Urbanski, W. Shih, O. Zagrijtschuk, C. Zimmerman, R. Mesa   +12 more
semanticscholar   +1 more source

Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia

Journal of Thrombosis and Haemostasis, 2022
Patients with essential thrombocythemia (ET) often experience bleeding associated with acquired von Willebrand syndrome (AVWS) when the platelet count is markedly increased.
Masayuki Kubo, K. Sakai, M. Hayakawa, H. Kashiwagi, H. Yagi, Y. Seki, Atsushi Hasegawa, Haruyuki Tanaka, I. Amano, Y. Tomiyama, M. Matsumoto   +10 more
semanticscholar   +1 more source

Mutations and thrombosis in essential thrombocythemia

Blood Cancer Journal, 2021
Dear Editor, Essential thrombocythemia (ET) constitutes one of the three JAK2/MPL/CALR-mutated myeloproliferative neoplasms (MPNs), which also include polycythemia vera (PV) and primary myelofibrosis (PMF).
P. Guglielmelli, N. Gangat, G. Coltro, T. Lasho, G. G. Loscocco, C. Finke, Erika Morsia, Benedetta Sordi, N. Szuber, C. Hanson, A. Pardanani, A. Vannucchi, A. Tefferi   +12 more
semanticscholar   +1 more source

Essential Thrombocythemia

Handbook of Hematologic Malignancies, 2020
Abnormal blood clotting (thrombosis) is common in people with essential thrombocythemia and causes many signs and symptoms of this condition. Clots that block blood flow to the brain can cause strokes or temporary stroke-like episodes known as transient ...
Nikesh N. Shah, Kenneth S. Zuckerman
semanticscholar   +1 more source